The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Development and Validation of a Sensitive Method for Measuring PRKN
Study Rationale: Mutations in the genes encoding PRKN and PINK1 are associated with Parkinson’s disease (PD). PINK1 and PPKN proteins work together to mediate the degradation of damaged mitochondria...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
-
Freezing of Gait, 2024TURN-IT: A Novel Intervention to Improve Turning in People with PD and Freezing of Gait
Study Rationale: Turning is a critical aspect of mobility for people with PD that, in some individuals, can precipitate freezing of gait. We recently developed a turn-specific intervention for people...
-
Alpha-synuclein Seed Amplification Assay Program, 2024Maximizing Sensitivity of Alpha-synuclein Seed Amplification Assays by Eliminating Spontaneous Aggregation
Study Rationale: A key characteristic of Parkinson’s disease (PD) is the formation of alpha-synuclein aggregates in the brain. The ability to detect these aggregates in body fluids is important for...
-
Freezing of Gait, 2024Use of Soft Robotic Apparel to Prevent Freezing of Gait in Parkinson’s Disease
Study Rationale: Freezing of gait (FoG) is a disabling walking problem that leads to loss of mobility, falling and poor quality of life in many people with Parkinson’s disease (PD). People with FoG...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.